Cargando…

Emergent dolutegravir resistance in integrase-naïve, treatment experienced patients from Zimbabwe

We report two cases of dolutegravir (DTG) resistance in highly treatment experienced patients. Monitoring for treatment failure and adherence support is important in highly treatment experienced patients taking DTG. WHAT THIS STUDY ADDS: Dolutegravir is the mainstay of HIV treatment programmes and e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mandikiyana Chirimuta, Linda A., Pascoe, Margaret J., Lowe, Sara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AOSIS 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634947/ https://www.ncbi.nlm.nih.gov/pubmed/36479423 http://dx.doi.org/10.4102/sajhivmed.v23i1.1435

Ejemplares similares

Cutaneous squamous cell carcinoma in vertically acquired HIV and epidermodysplasia verruciformis
por: Mandikiyana Chirimuta, Linda A., et al.
Publicado: (2022)

A case report of untreatable HIV infection in Harare, Zimbabwe
por: Chimbetete, Cleophas, et al.
Publicado: (2019)

Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review
por: Tao, Kaiming, et al.
Publicado: (2023)

Low Prevalence of Pre-Treatment and Acquired Drug Resistance to Dolutegravir among Treatment Naïve Individuals Initiating on Tenofovir, Lamivudine and Dolutegravir in Zimbabwe
por: Kouamou, Vinie, et al.
Publicado: (2023)

Emergence of Resistance to Integrase Strand Transfer Inhibitors during Dolutegravir Containing Triple-Therapy in a Treatment-Experienced Patient with Pre-Existing M184V/I Mutation
por: Braun, Dominique L., et al.
Publicado: (2020)

Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study
por: Underwood, Mark, et al.
Publicado: (2022)

Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Naive and Treatment-Experienced Patients in Canada
por: Despiégel, Nicolas, et al.
Publicado: (2015)

HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland
por: Parczewski, Miłosz, et al.
Publicado: (2012)

In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2
por: Smith, Robert A, et al.
Publicado: (2015)

HIV integrase variability and genetic barrier in antiretroviral naïve and experienced patients
por: Piralla, Antonio, et al.
Publicado: (2011)

Probing Resistance Mutations in Retroviral Integrases by Direct Measurement of Dolutegravir Fluorescence
por: Thierry, Eloïse, et al.
Publicado: (2017)

Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor–Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance
por: Demarest, James, et al.
Publicado: (2018)

Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study
por: Vavro, Cindy, et al.
Publicado: (2022)

Safety and efficacy of elvitegravir, dolutegravir, and raltegravir in a real-world cohort of treatment-naïve and -experienced patients
por: Brehm, Thomas Theo, et al.
Publicado: (2019)

Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades
por: Doyle, Tomas, et al.
Publicado: (2015)

7‐Step Flow Synthesis of the HIV Integrase Inhibitor Dolutegravir
por: Ziegler, Robert E., et al.
Publicado: (2018)

Biochemical activity of RAGs is impeded by Dolutegravir, an HIV integrase inhibitor
por: Nilavar, Namrata M., et al.
Publicado: (2020)

Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV
por: Dow, Dorothy E., et al.
Publicado: (2014)

The use of integrase inhibitors in treatment-experienced patients
por: Gatell, Jose M
Publicado: (2009)

Resistance in Patients Failing Integrase Strand Transfer Inhibitors: A Call to Replace Raltegravir With Dolutegravir in Third-Line Treatment in South Africa
por: Steegen, Kim, et al.
Publicado: (2019)

Emerging role of integrase inhibitors in the management of treatment-experienced patients with HIV infection
por: Katlama, Christine, et al.
Publicado: (2009)

Limited emergence of resistance to integrase strand transfer inhibitors (INSTIs) in ART-experienced participants failing dolutegravir-based antiretroviral therapy: a cross-sectional analysis of a Northeast Nigerian cohort
por: Abdullahi, Adam, et al.
Publicado: (2023)

Dolutegravir Interactions with HIV-1 Integrase-DNA: Structural Rationale for Drug Resistance and Dissociation Kinetics
por: DeAnda, Felix, et al.
Publicado: (2013)

Emergence of the G118R Pan-Integrase Resistance Mutation as a Result of Low Compliance to a Dolutegravir-Based cART
por: Mens, Helene, et al.
Publicado: (2022)

Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients
por: Zhang, Jianping, et al.
Publicado: (2015)

Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy
por: Mahomed, Kairoonisha, et al.
Publicado: (2020)

Factors associated with HIV-1 resistance to integrase strand transfer inhibitors in Spain: Implications for dolutegravir-containing regimens
por: Gil, Horacio, et al.
Publicado: (2022)

Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir
por: Song, Ivy, et al.
Publicado: (2014)

Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients
por: Radford, Matthew, et al.
Publicado: (2019)

Cervical human papillomavirus prevalence, risk factors and outcomes in a cohort of HIV-infected women in Harare, Zimbabwe
por: Mandiriri, Ardele M., et al.
Publicado: (2020)

An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor–based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1
por: Evitt, Lee A., et al.
Publicado: (2023)

High-level dolutegravir resistance can emerge rapidly from few variants and spread by recombination: implications for integrase strand transfer inhibitor salvage therapy
por: Huik, Kristi, et al.
Publicado: (2022)

HIV-2 Integrase Variation in Integrase Inhibitor-Naïve Adults in Senegal, West Africa
por: Gottlieb, Geoffrey S., et al.
Publicado: (2011)

The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound
por: Wainberg, Mark, et al.
Publicado: (2014)

How Polypurine Tract Changes in the HIV-1 RNA Genome Can Cause Resistance against the Integrase Inhibitor Dolutegravir
por: Das, Atze T., et al.
Publicado: (2018)

Sexually transmitted infections, the silent partner in HIV-infected women in Zimbabwe
por: Lowe, Sara, et al.
Publicado: (2019)

Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Experienced (TE) Patients in France
por: Pialoux, Gilles, et al.
Publicado: (2015)

Drug Resistance to HIV-1 Integrase Inhibitors Among Treatment-Naive Patients in Beijing, China
por: Yu, Fengting, et al.
Publicado: (2022)

Canary in the Coal Mine? Transmitted Mutations Conferring Resistance to All Integrase Strand Transfer Inhibitors in a Treatment-Naive Patient
por: McGee, Kara S, et al.
Publicado: (2018)

Dolutegravir Resistance in Malawi’s National HIV Treatment Program
por: van Oosterhout, Joep J, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_eriuqcdkkogc7luv3lb2pln3i5